Helsinn Therapeutics (U.s.), Inc.

Helsinn Therapeutics (U.S.), Inc., operating as Helsinn Therapeutics US Inc., is a for-profit pharmaceutical manufacturer based in Iselin, New Jersey, that supplies specialized oncology pharmaceuticals to federal healthcare facilities as a prime contractor under full-and-open competitive vehicles with no SBA set-aside designations. The vendor operates exclusively as a prime (100% of recent awards) and holds no subcontracting footprint.

Helsinn's federal capability centers on the supply of VALCHLOR gel (0.01265% topical formulation), a specialized pharmaceutical indicated for cutaneous T-cell lymphoma treatment. The company holds two active federal vehicles: a Federal Supply Schedule contract under Pharmaceuticals and Drugs (FSS-61-IB) with a $33.6 million ceiling through February 2030, awarded March 1, 2025, and a single-award Blanket Purchase Agreement under the same schedule with an $8.3 million ceiling through March 11, 2027, awarded March 12, 2025. Both vehicles operate without set-asides and support direct ordering by federal agencies. Representative delivery orders include six monthly orders from Federal Correctional Institution Fort Worth (February through September 2026, $5,984.59 each) and orders from Federal Medical Center Carswell and Veterans Integrated Service Network facilities. A prior BPA with the Department of Veterans Affairs National Acquisition Center ($15.5 million ceiling) was cancelled in favor of the current arrangement.

Customer concentration is heavily weighted to the Department of Veterans Affairs. The top three customer entities account for 89% of awards: Veterans Integrated Service Network 12 holds 3 awards with $36.9 million combined potential value, the VA National Acquisition Center holds 3 awards with $28.2 million combined potential value, and Veterans Integrated Service Network 6 holds 3 awards with $109 thousand combined potential value. The Department of Justice Bureau of Prisons Federal Correctional Institution Fort Worth places recurring monthly orders (7 awards, $42 thousand combined potential value). The divergence between award count and potential value reflects the contrast between high-ceiling IDVs anchoring the VA relationship and small-dollar monthly delivery orders from correctional facilities. Combined potential value across all awards totals $65.3 million, though obligated dollars remain minimal at $188 thousand, indicating standing BPA ceilings that draw orders incrementally.

Activity shows growth in recent years: two awards in 2018, three in 2019, one in 2023, three in 2025, and eight in 2026. The vendor's footprint is concentrated in PSC Drugs and Biologicals (17 awards). Helsinn competes exclusively under the Pharmaceuticals and Drugs GSA Schedule vehicle, which carries 17 task orders with $28.5 million combined potential value. The vendor maintains no disclosed subcontract relationships and does not pursue federal work through teaming arrangements or prime-to-prime partnerships.